Pepper Bio
Monday, June 03, 2024
Company Presentation
Oncology
Company Presentation Theater 4
Pepper Bio, the world's first transomics drug discovery company, leverages its proprietary database and analytics to identify promising first-in-class therapies, rediscover new uses for existing therapeutics, and rescue drugs in development on a path toward failure.
By deciphering the root causes of diseases to identify effective treatments, Pepper Bio illuminates the fastest, safest path to drug discovery. Its AI-driven platform, COMPASS, is built on the world's first and largest proprietary transomics database, integrating genomic, transcriptomic, proteomic, and phosphoproteomic data.
This holistic approach offers a full-picture understanding of biological systems—like driving using all your mirrors to know the impact of where other cars are on the road. Unlike other companies that focus on measuring gene and protein expression levels, Pepper Bio not only identifies what's present in a disease but also understands the activities and reasons behind these occurrences.
Company Website:
https://pepper.bio/
Lead Product in Development:
Pepper’s transomic bioplatform, COMPASS, integrates genomic, transcriptomic, proteomic, and phosphoproteomic data to help researchers repeatedly and predictably discover drugs to treat untreatable diseases.
Company HQ City
Dedham
Company HQ State
MA
Company HQ Country
United States
CEO/Top Company Official
Jon Hu
Development Phase of Primary Product
Discovery
Speakers